Ubl’s remarks come as the Trump administration weighs potential candidates to lead the agency who have suggested they would radically change how it vets new drugs.
Asked by STAT about the notion that the FDA should no longer evaluate drugs for effectiveness, Ubl was unambiguous: “We believe that the FDA review process is the gold standard and should remain so.”
Robbins reports that Mr. Ubl wouldn’t comment on specific candidates rumored to be under consideration to lead the FDA, which reportedly include Jim O’Neill, the Silicon Valley libertarian, and Fairleigh Dickinson’s Dr. Joseph Gulfo, who has called for scaling back the requirements for approval.
The gathering was put on by the events division of The Atlantic magazine and sponsored by PhRMA.
Tuesday’s event was the first stop on PhRMA’s barnstorming tour to bolster the industry’s image as part of the “Go Boldly” campaign.
For the full story, click here.
Follow Rebecca Robbins on Twitter @rebeccadrobbins.
Follow STAT — which reports from the frontiers of health and medicine — on Twitter @statnews.